drug
BALVERSA
updated 5mo agoby Janssen Biotech Inc
community read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying BALVERSA
- phase2An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
- phase1A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
- phase3A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
- phase2Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- phase2A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
- phase2A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
- phase2A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- phase2Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
News(2)
- Tyra disappoints investors with bladder cancer dataRemission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.biopharma_dive · 24d ago
- Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stockTyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But the biotech’s stock fell in premar…fiercebiotech · 24d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that